Anavex Life Sciences Corp (AVXL)

[TempePhil]

Interesting notes on TGDs presentation:
He obviously has the much of Alz data in hand.
If he knew of ANY problems with the Alz data, he would have probably been doing some backpedaling, or 're-explaining' during the presentation. He did not back track on anything. The slides were exactly as previous presentations. Instead, for example, regarding the Sigma 1 WT gene, he actually highlighted the variant vs. WT, whereas I thought he had been minimizing the differences in recent presentations.

Was it my imagination or did TGD seem to be emphasizing the similarities between the Alz and the PDD trial, as if to say, expect Alz results to be like the PDD results. Of course there is the slide where "70% of genes which are known to have pathological implications in both alzheimer and in Parkinson", which he went over.
Then the PDD episodic memory slide, where he said, the medium dose stopped the decline, which is already fantastic, but the high dose group was above baseline.
TGD then said, but the reason I want to remember these doses is they are exactly the same doses in the upcoming Alzheimer study - placebo 30, 50. This episodic memory test is highly correlated to the ADAS-COG (Alz), which was published many years ago.
A little later he said --Remember this Adas-cog which you will see in a few slides, is also the Alz primary endpoint. So it is quite intriguing to see this data.--

When my teachers said 'Remember this', it was important and would be on the test!